Form 4: Cellectar Biosciences COO Granted Stock Options Following Stockholder Approval
SEC Form 4 Filing
Jarrod Longcor, Chief Operating Officer of Cellectar Biosciences, receives stock options after stockholder approval of the amended 2021 Stock Incentive Plan.
Summary
- Jarrod Longcor, the Chief Operating Officer of Cellectar Biosciences, was granted stock options on June 14, 2024.
- This grant follows the approval by Cellectar's stockholders of the amended 2021 Stock Incentive Plan at the company's 2024 Annual Meeting of Stockholders.
- The stock option allows Longcor to purchase 500,000 shares of Cellectar's common stock at an exercise price of $2.65 per share.
- The options vest over three years from December 15, 2023, with one-third vesting on the first anniversary and the remainder in 24 equal monthly installments.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns management interests with shareholders. The approval of the stock incentive plan is also a positive sign.
Positives
- The granting of stock options to the COO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the COO.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholder value.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen routinely use stock options to incentivize their executives.
- The vesting schedule of three years is also typical, aligning with industry norms for long-term performance incentives.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the COO to drive company performance.
- Employees may see this as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| December 15, 2023 | Date the option was contingently granted and vesting period begins. |
| June 14, 2024 | Date of stockholder approval of the amended 2021 Stock Incentive Plan and the official grant date of the options. |
| December 15, 2033 | Expiration date of the stock options. |
Keywords
stock options, Cellectar Biosciences, Jarrod Longcor, COO, stockholder approval, 2021 Stock Incentive Plan, equity compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.